Fixing stem cells via genome editing: hope for cystic fibrosis?

Free Editorial on gene editing as a potential therapeutic approach for cystic fibrosis.

Jan 25, 2016

The primary defect in cystic fibrosis is the result of a mutation to a single gene, CFTR, making it a prime target for gene therapy. In this free-to-access Regenerative Medicine Editorial, author Brian R Davis from University of Texas Health Science Center (TX, USA) looks at different gene-editing approaches for cystic fibrosis.

David BR. Fixing stem cells via genome editing: hope for cystic fibrosis? Regen. Med. 11(1), 1–3, doi:10.2217/rme.15.84 (2016).

Regenerative Medicine

Journal, Future Science Group

Regenerative Medicine is an award-winning peer-reviewed journal, in print and web formats. The journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering this essential information in concise, clear and attractive article formats. Among other indexing services Regenerative Medicine is listed by MEDLINE/Index Medicus, EMBASE/Excerpta Medica, Chemical Abstracts, Science Citation Index Expanded™ (SciSearch®), Emcare, Biological Abstracts, BIOSIS Previews, Biotechnology Citation Index®, Journal Citation Reports/Science Edition®, Scopus® with an Impact Factor of 2.786 (2014). Each issue contains expertly drafted Reviews, Original Research articles, Perspectives, Editorials, topical insight from international leaders in their field, and additional added-value content. The Senior Editor of the journal is Professor Chris Mason, University College London. You can find out more about Regenerative Medicine at our website (, where you can find the aims and scope of the journal and details of our international editorial board.

No comments yet.